SkinBioTherapeutics plc (AIM:SBTX)

SkinBioTherapeutics Income Statement

Financials in millions GBP. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Operating Revenue	2.68	1.21	0.13	0.07	-	-
Revenue	2.68	1.21	0.13	0.07	-	-
Revenue Growth (YoY)	1557.07%	815.26%	76.64%	-	-	-
Cost of Revenue	1.19	0.53	0.05	0.03	-	-
Gross Profit	1.49	0.68	0.09	0.05	-	-
Selling, General & Admin	3.72	3.03	2.15	2.17	0.99	0.98
Research & Development	0.33	0.56	0.93	0.86	0.51	0.64
Operating Expenses	4.05	3.59	3.08	3.03	1.5	1.62
Operating Income	-2.55	-2.91	-3	-2.98	-1.5	-1.62
Interest Expense	-0.05	-0.04	-0.01	-0.01	-0	-
Pretax Income	-2.6	-2.95	-3.01	-2.99	-1.5	-1.62
Income Tax Expense	-0.02	-0.07	-0.17	-0.2	-0.07	-0.12
Net Income	-2.58	-2.88	-2.84	-2.79	-1.43	-1.5
Net Income to Common	-2.58	-2.88	-2.84	-2.79	-1.43	-1.5
Shares Outstanding (Basic)	209	186	165	157	147	128
Shares Outstanding (Diluted)	209	186	165	157	147	128
Shares Change (YoY)	19.79%	13.10%	5.06%	6.87%	14.53%	4.95%
EPS (Basic)	-0.01	-0.02	-0.02	-0.02	-0.01	-0.01
EPS (Diluted)	-0.01	-0.02	-0.02	-0.02	-0.01	-0.01
Free Cash Flow	-2.16	-2.74	-2.73	-2.67	-1.56	-0.89
Free Cash Flow Per Share	-0.01	-0.01	-0.02	-0.02	-0.01	-0.01
Gross Margin	55.71%	56.51%	64.51%	60.64%	-	-
Operating Margin	-95.36%	-240.36%	-2271.26%	-3988.83%	-	-
Profit Margin	-96.14%	-237.95%	-2146.91%	-3735.37%	-	-
Free Cash Flow Margin	-80.71%	-226.80%	-2071.02%	-3575.44%	-	-
EBITDA	-2.31	-2.77	-2.99	-2.98	-1.5	-1.61
EBITDA Margin	-86.20%	-229.38%	-	-	-	-
D&A For EBITDA	0.25	0.13	0.01	0	0	0.01
EBIT	-2.55	-2.91	-3	-2.98	-1.5	-1.62
EBIT Margin	-95.36%	-240.36%	-	-	-	-

Updated Dec 10, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.